Ritonavir, Drugs Monitor

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

June 13, 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. https://doi.org/10.1101/2020.06.05.20123299 The aim of this retrospective intent-to-treat analysis of the hospitalized patients was to compare the rate of clinical improvement between… Continue reading "(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19"

(08 May 2020) Clinical trial findings- early triple antiviral combination effective

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext In a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19, shortening in… Continue reading

Tag: Ritonavir

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

(08 May 2020) Clinical trial findings- early triple antiviral combination effective